Get the Stockscreener App
0.7995
9.82%
0.0715
After Hours:
.79
-0.0095
-1.19%
iBio Inc stock is traded at $0.7995, with a volume of 673.65K.
It is up +9.82% in the last 24 hours and down -18.41% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$0.728
Open:
$0.72
24h Volume:
673.65K
Relative Volume:
0.57
Market Cap:
$13.21M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.1206
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
+3.39%
1M Performance:
-18.41%
6M Performance:
-64.93%
1Y Performance:
-55.83%
1-Day Range:
$0.72
$0.8184
1-Week Range:
$0.70
$0.8187
52-Week Range:
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.7995 | 12.77M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World
Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister
Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO Stock News - GuruFocus
iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World
iBio announces new preclinical data for Activin E antibody - TipRanks
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Pri - GuruFocus
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus
iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat - GlobeNewswire
Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan
iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks
iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World
IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results - The Manila Times
iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq
iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan
Take off with iBio Inc (IBIO): Get ready for trading - Sete News
Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com
iBio Raises $6.2 Million Through Warrant Inducement Transaction - GuruFocus
iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus
Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan
What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com
Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com
iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World
An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel
Analytical Overview: TMC the metals company Inc (TMC)’s Ratios Tell a Financial Story - DWinneX
Quarterly Snapshot: Quick and Current Ratios for iBio Inc (IBIO) - DWinneX
iBio - The Pharma Letter
AstralBio - The Pharma Letter
iBio Inc (IBIO) expanding its growth trajectory ahead - Sete News
Off-market insider buying at Tantalex Lithium Resource (TTX) - The Globe and Mail
Monitoring iBio Inc (IBIO) after recent insider movements - knoxdaily.com
iBio Enters Licensing Agreement for Obesity Treatment - MSN
In the Green: iBio Inc (IBIO) Closes at 0.70, Up/Down -17.43 from Previous Day - DWinneX
Ibio Inc Enters Exclusive License Agreement With AstralBio - marketscreener.com
iBio Inc (IBIO) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Breaking down IBIO’s current quarter earnings estimates - uspostnews.com
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - The Manila Times
Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal - Stock Titan
Porch Group Inc (PRCH) Stock: A Year of Stock Market Dynamics - investchronicle.com
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):